Transforming growth factor beta expression by human vascular cells inhibits interferon gamma production and arterial media injury by alloreactive memory T cells

American Journal of Transplantation

Volumn 11, Issue 11, 2011, Pages 2332-2341

  Lebastchi, A H ^a   Khan, S F ^a   Qin, L ^a   Li, W ^a   Zhou, J ^a   Hibino, N ^a   Yi, T ^a   Rao, D A ^a   Pober, J S ^a   Tellides, G ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Arteriosclerosis; Endothelial cells; Interferon c; Smooth muscle cells; T cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTERY INJURY; ARTERY MEDIA; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ARTERIOSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; ENDOTHELIUM, VASCULAR; HUMANS; INTERFERON-GAMMA; MICE; T-LYMPHOCYTE SUBSETS; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84857195891     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03676.x     Document Type: Article

References (41)

1. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 2006; 6: 508-519. (Pubitemid 43980523)
2. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387-397. (Pubitemid 32441591)
3. Tellides G, Pober JS. Interferon-gamma axis in graft arteriosclerosis. Circ Res 2007; 100: 622-632.
4. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010; 28: 445-489.
5. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein Edeficient mice. Am J Pathol 2003; 163: 1117-1125. (Pubitemid 37040147)
6. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119: 1424-1432.
7. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003; 112: 1342-1350. (Pubitemid 38057688)
8. Gojova A, Brun V, Esposito B, et al. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003; 102: 4052-4058. (Pubitemid 37486988)
9. Koglin J, Glysing-Jensen T, Räis änen-Sokolowski A, Russell ME. Immune sources of transforming growth factor-beta1 reduce transplant arteriosclerosis: Insight derived from a knockout mouse model. Circ Res 1998; 83: 652-660. (Pubitemid 28427749)
10. Letterio JJ, Roberts AB. Regulation of immune responses by TGFbeta. Annu Rev Immunol 1998; 16: 137-161.
11. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
12. Santarlasci V, Maggi L, Capone M, et al. TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 2009; 39: 207-215.
13. Das J, Ren G, Zhang L, et al. 2009. Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med 2009; 206: 2407-2416.
14. Sallusto F,Geginat J, Lanzavecchia A. Centralmemory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763. (Pubitemid 38680440)
15. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267-2275. (Pubitemid 29382237)
16. Li MO, Flavell RA. TGF-beta: A master of all T cell trades. Cell 2008; 134: 392-404.
17. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-869. (Pubitemid 47622560)
18. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease.NEngl JMed 2000; 342: 1350-1358. (Pubitemid 30408720)
19. Shiao SL, Kirkiles-Smith NC, Shepherd BR, McNiff JM, Carr EJ, Pober JS. Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol 2007; 179: 4397-4404.
20. Zhang P, Manes TD, Pober JS, Tellides G. Human vascular smooth muscle cells lack essential costimulatory molecules to activate allogeneic memory T cells. Arterioscler Thromb Vasc Biol 2010; 30: 1795-1801.
21. Wang Y, Burns WR, Tang PC, et al. Interferon-gamma plays a nonredundant role in mediating T cell-dependent outward vascular remodeling of allogeneic human coronary arteries. FASEB J 2004; 18: 606-608.
22. Tereb DA, Kirkiles-Smith NC, Kim RW, et al. Human T cells infiltrate and injure pig coronary artery grafts with activated but not quiescent endothelium in immunodeficient mouse hosts. Transplantation 2001; 71: 1622-1630. (Pubitemid 32574165)
23. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121.
24. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 1991; 88: 904-910.
25. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. 1992. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 1992; 90: 1582-1592.
26. Bahadori L, Milder J, Gold L, Botney M. Active macrophageassociated TGF-beta co-localizes with type I procollagen gene expression in atherosclerotic human pulmonary arteries. AmJ Pathol 1995; 146: 1140-1149.
27. Bobik A, Agrotis A, Kanellakis P, et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 1999; 99: 2883-2891. (Pubitemid 29258976)
28. Metcalfe JC, Grainger DJ. Transforming growth factor-beta and the protection from cardiovascular injury hypothesis. Biochem Soc Trans 1995; 23: 403-406.
29. Mallat Z, Gojova A,Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype inmice. Circ Res 2001; 89: 930-934. (Pubitemid 34627899)
30. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-462. (Pubitemid 24263550)
31. Borkowski P, Robinson MJ, Kusiak JW, Borkowski A, Brathwaite C, Mergner WJ. Studies on TGF-beta 1 gene expression in the intima of the human aorta in regions with high and low probability of developing atherosclerotic lesions. Mod Pathol 1995; 8: 478-482.
32. Xie JJ, Wang J, Tang TT, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010; 49: 185-193.
33. Nadig SN,Wieckiewicz J,Wu DC, et al. 2010. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809-813.
34. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-644. (Pubitemid 32844773)
35. Longenecker G, Thyagarajan T, Nagineni CN, et al. Endocrine expression of the active form of TGF-beta1 in the TGF-beta1 nullmice fails to ameliorate lethal phenotype. Cytokine 2002; 18: 43-50. (Pubitemid 34762077)
36. Watanabe M, Sangawa A, Sasaki Y, et al. Distribution of inflammatory cells in adventitia changed with advancing atherosclerosis of human coronary artery. J Atheroscler Thromb 2007; 14: 325-331.
37. van Loosdregt J, van Oosterhout MF, Bruggink AH, et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 2006; 114: 1599-1607. (Pubitemid 44547430)
38. Dal Canto AJ, Swanson PE, O'Guin AK, Speck SH, Virgin HW. IFNgamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest 2001; 107: R15-22. (Pubitemid 32096842)
39. Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle cells by interferongamma contributes to medial immunoprivilege. J Immunol 2007; 179: 5246-5254.
40. Ahmad U, Ali R, Lebastchi AH, et al. IFN-gamma primes intact human coronary arteries and cultured coronary smooth muscle cells to double-stranded RNA-and self-RNA-induced inflammatory responses by upregulating TLR3 and melanoma differentiationassociated gene 5. J Immunol 2010; 185: 1283-1294.
41. Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-b signalling. Nature 2010; 467: 967-971.